GlobeNewswire·May 27, 2026, 4:05 PM ET

Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy

Zentalis Pharmaceuticals appointed Shannon Campbell to its Board of Directors to leverage her 30+ years of oncology commercial experience.
Sarah Kelly joined as Senior Vice President of Commercial Strategy to lead launch readiness for azenosertib & its companion diagnostic.
These appointments aim to build commercial & operational capabilities as Zentalis advances azenosertib in registrational Phase 2 & Phase 3 trials for Cyclin E1-positive platinum-resistant ovarian cancer (PROC).
Zentalis expects a topline readout from the DENALI Phase 2 trial by year-end 2026 to support a potential accelerated FDA approval pathway.
The company recently dosed the first patient in the ASPENOVA Phase 3 confirmatory trial designed to support full approval & ex-U.S. registrations.
Azenosertib is an investigational first-in-class WEE1 inhibitor granted Fast Track Designation for treating Cyclin E1-positive PROC patients.
Approximately 50% of PROC patients have Cyclin E1 overexpression, a biomarker currently being validated in the DENALI & ASPENOVA trials.
Shannon Campbell previously served as Chief Commercial Officer at Merus & held senior roles at Novartis & Bayer Healthcare.
Sarah Kelly brings 30 years of experience in commercial leadership at companies including Amgen, Turning Point, Spectrum, & Agilent.